浙江佐力药业股份有限公司 内部审计制度 第一章 总则 第一条 为了规范浙江佐力药业股份有限公司（以下简称"公司"）内部审 计工作， 提高内部审计工作质量，保护投资者合法权益，根据《中华人民共和 国审计法》《审计署关于内部审计工作的规定》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》等有关法律、法规、规章和规范性文件的规定，结合公司实际情况，制 定本制度。 第二条 本制度适用于公司各内部机构、控股子公司以及具有重大影响的参 股子公司的与公司治理、财务报告和信息披露事务相关的所有业务环节所进行的 内部审计工作。 第三条 本制度所称内部审计，是指由公司内部机构或人员，对公司内部控 制和风险管理的有效性、财务信息的真实性和完整性以及经营活动的效率和效果 等开展的一种评价活动。 第四条 本制度所称内部控制，是指公司董事会、监事会、高级管理人员及 其他有关人员为实现下列目标而提供合理保证的过程： （四）确保公司信息披露的真实、准确、完整和公平。 第五条 公司董事会应当对内部控制制度的建立健全和有效实施负责，重要 的内部控制制度应当经董事会审议通过。 公司董事 ...

浙江佐力药业股份有限公司 重大信息内部报告制度 第一章 总则 第一条 为规范浙江佐力药业股份有限公司（以下简称"本公司"或"公 司"）重大信息内部报告工作的管理，保证公司内部重大信息的快速传递、归集 和有效管理，及时、准确、全面、完整地披露信息，明确公司各部门、各子公司 及有关人员重大信息内部报告的程序和职责，维护投资者的合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关法律、法规、规章、规范性文件 和本公司《章程》的有关规定，结合公司实际情况，制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对公 司股票及其衍生品种交易价格产生较大影响的情形或事件（以下简称"重大信息"、 "重大事件"或"重大事项"）时，按照本制度规定负有报告义务的有关人员， 应当在第一时间将相关信息向公司责任领导、董事会秘书、董事长进行报告，确 保董事会秘书第一时间获悉公司重大信息的制度。董事会秘书需了解重大事项的 情况和进展时，相关部门（包括公司全资、 ...

浙江佐力药业股份有限公司 董事、监事薪酬管理制度 第一章 总则 第一条 为进一步完善浙江佐力药业股份有限公司（以下简称"公司"）董 事、监事的薪酬管理，建立和完善激励约束机制，有效地调动董事、监事的工作 积极性，提高公司经营管理水平，促进公司健康、持续、稳定发展，根据《中华 人民共和国公司法》、《上市公司独立董事管理办法》、《深圳证券交易所创业板股 票上市规则》等法律、法规及《公司章程》的有关规定，特制定本制度。 第二条 董事、监事是指公司董事会、监事会的全部在职成员；其中，董事 由内部董事、外部董事、独立董事构成；监事由内部监事、外部监事构成。 （一）内部董事，指与公司之间签订聘任合同或劳动合同的公司员工或公司 管理人员兼任的非独立董事； （二）外部董事，指不在公司担任除董事外的其他职务的非独立董事； （三）独立董事，指公司按照《上市公司独立董事管理办法》的规定聘请的， 不在公司担任除董事外的其他职务，并与公司及主要股东、实际控制人不存在直 接或者间接利害关系，或者其他可能影响其进行独立客观判断关系的董事； （四）内部监事，指与公司之间签订聘任合同或劳动合同的公司员工或公司 管理人员兼任的监事（包括职工监事 ...

浙江佐力药业股份有限公司 2024年度独立董事述职报告 ——朱建 各位股东及股东代表： 本人作为浙江佐力药业股份有限公司（以下简称"公司"）的独立董事，在 2024 年严格按照《公司法》《证券法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 《上市公司独立董事管理办法》等有关法律法规、规范性文件和《公司章程》《独 立董事制度》等规定，本着对全体股东负责的态度，诚实、勤勉、独立地履行职责， 积极出席相关会议，认真审议董事会各项议案，并以谨慎的态度对相关事项发表意 见，同时充分发挥独立董事及各专门委员会委员的作用，积极维护公司利益和股东 特别是中小股东的利益。现将本人 2024 年的工作情况作汇报如下： 一、独立董事的基本情况 （一）个人简历 本人朱建，1970 年 7 月出生，中国国籍，无境外永久居留权，工商管理硕士， 正高级会计师、注册资产评估师、注册税务师。曾任钱江水利开发股份有限公司 财务总监、董事会秘书等职务。现任本公司独立董事、杭州尚祥科技有限公司执 行董事兼总经理、浙江众鑫环保科技集团股份有限公司财务总监、浙江金盾风机 股份有限公司 ...

浙江佐力药业股份有限公司 舆情管理制度 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道、不实报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 舆情信息的分类： 第一章 总则 第一条 为提高浙江佐力药业股份有限公司（以下简称"公司"）应对各类舆 情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股价、 商业信誉及正常生产经营活动造成的影响，切实维护投资者合法权益，根据《深 圳证券交易所创业板股票上市规则》等相关法律、法规和规范性文件及《公司章 程》的规定，结合公司实际情况，制定本制度。 （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动， 使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易价格变 动的负面舆情。 （二）一般舆情：指除重大舆情之外的其他舆情。 第四条 本制度适用于本公司及合并报表范围内的各子公司。 第七条 舆情工作组是公司应对各类舆情处 ...

浙江佐力药业股份有限公司 2024年度独立董事述职报告 ——姚杰 各位股东及股东代表： 本人作为浙江佐力药业股份有限公司（以下简称"公司"）的第八届董事会独 立董事，根据《公司法》《上市公司独立董事管理办法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》及其他有关法律法规、规范性文件和《公司章程》《独立董事制度》 等规定，忠实履行独立董事的职责，积极出席公司相关会议，认真审议董事会各项 议案，充分发挥独立董事的作用，切实维护了公司和全体股东的利益，尤其是中小 股东的合法权益。现就本人2024年任期内的工作情况作汇报如下： 一、独立董事的基本情况 （一）个人简历 本人姚杰，1989年2月出生，中国国籍，无境外永久居留权，本科学历，四 级律师。曾任浙江三星新材股份有限公司独立董事。现任浙江莫干山律师事务所 律师、合伙人。2024年5月10日起担任公司独立董事。 （二）独立性说明 在担任公司独立董事期间，本人未在公司担任独立董事及董事会各相关专门 委员会委员以外的任何职务，也未在公司主要股东单位担任任何职务，与公司及 主要股东之间不存在利害关系或其他可 ...

浙江佐力药业股份有限公司董事会 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等要求，浙江佐力药业股份有限公司（以下简称"公司"） 董事会就公司现任独立董事朱建先生、王萍先生、姚杰先生的独立性情况进行评 估，并出具如下专项意见： 经核查公司独立董事朱建先生、王萍先生、姚杰先生的兼职、任职情况以及 其签署的独立性自查情况报告，上述人员未在公司担任独立董事及董事会各相关 专门委员会委员以外的任何职务，也未在公司主要股东单位担任任何职务，与公 司及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系， 因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规及《公司章 程》《独立董事制度》中对独立董事任职资格及独立性的要求。 浙江佐力药业股份有限公司 董 事 会 2025 年 4 月 25 日 ...

浙江佐力药业股份有限公司 2024年度独立董事述职报告 ——潘斌 各位股东及股东代表： 本人作为浙江佐力药业股份有限公司（以下简称"公司"）的第七届董事会独立 董事，根据《公司法》《上市公司独立董事管理办法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》及其他有关法律法规、规范性文件和《公司章程》《独立董事制度》 等规定，忠实履行独立董事的职责，积极出席公司相关会议，认真审议董事会各项 议案，充分发挥独立董事的作用，切实维护了公司和全体股东的利益，尤其是中小 股东的合法权益。现就本人2024年任期内的工作情况作汇报如下： 一、独立董事的基本情况 （一）个人简历 本人潘斌，1972年12月出生，中国国籍，无境外永久居留权，法学硕士。曾 任南方证券有限公司投资银行部副总经理、上海东方华银律所首席合伙人等职务。 现任上海虎博投资管理有限公司执行董事兼总经理、上海卓易科技股份有限公司 董事、浙江运达风电股份有限公司独立董事、广西桂冠电力股份有限公司独立董 事等职务。曾任公司独立董事，因公司第七届董事会任期届满，于2024年5月10 日卸任公司独立董事职务 ...

Financial Performance - The company's revenue for Q1 2025 was ¥824,425,237.08, representing a year-on-year increase of 22.52% compared to ¥672,899,096.57 in the same period last year[4]. - The net profit attributable to shareholders was ¥181,151,432.46, up 27.20% from ¥142,415,333.77 in the previous year[4]. - The company reported a basic earnings per share of ¥0.2583, reflecting a 27.24% increase from ¥0.2030 in the same period last year[4]. - The company's net profit margin improved, with net profit attributable to the parent company increasing to ¥1,028,239,002.42, compared to ¥847,087,569.96 previously, reflecting a growth of 21.4%[16]. - The net profit for the current period is CNY 183,386,181.52, an increase of 27.3% compared to CNY 144,106,493.76 in the previous period[19]. - The total comprehensive income for the current period is CNY 305,543,707.70, up from CNY 135,283,665.64 in the previous period, representing a growth of 126.5%[19]. - Basic and diluted earnings per share for the current period are both CNY 0.2583, compared to CNY 0.2030 in the previous period, reflecting a 27.2% increase[19]. Cash Flow - The net cash flow from operating activities was -¥77,438,380.01, a significant decrease of 553.72% compared to ¥17,067,450.04 in the same period last year[4]. - The net cash outflow from operating activities was 77.44 million yuan, an increase of 94.51 million yuan year-on-year, representing a growth of 553.72%[10]. - The net cash outflow from investing activities was 129.98 million yuan, an increase of 204.14 million yuan year-on-year, representing a growth of 275.27%[10]. - The net cash inflow from financing activities was 140.08 million yuan, an increase of 162.73 million yuan year-on-year, representing a growth of 718.67%[10]. - Cash flow from operating activities shows a net outflow of CNY -77,438,380.01, a decline from a net inflow of CNY 17,067,450.04 in the previous period[21]. - Cash flow from investing activities results in a net outflow of CNY -129,980,161.09, compared to a net inflow of CNY 74,160,686.49 in the previous period[21]. - Cash flow from financing activities shows a net inflow of CNY 140,083,303.45, a significant improvement from a net outflow of CNY -22,642,770.73 in the previous period[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,569,270,953.55, an increase of 14.46% from ¥3,991,955,854.40 at the end of the previous year[4]. - Current assets totaled ¥2,436,673,465.92, a rise of 11.9% from ¥2,177,445,545.68 at the beginning of the period[16]. - Non-current assets increased to ¥2,132,597,487.63, up 17.5% from ¥1,814,510,308.72[16]. - Current liabilities rose to ¥1,211,726,378.45, an increase of 14.7% from ¥1,056,049,174.34[16]. - Non-current liabilities totaled ¥176,247,420.58, up 51.5% from ¥116,465,923.94[16]. - The company's total liabilities increased, with short-term borrowings rising by 22.23% to ¥46,119.37 million[8]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,228[11]. - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, totaling 129,890,463 shares, with 64,500,000 shares pledged[11]. - The company plans to grant 5.855 million restricted stocks at a price of 8.07 yuan per share as part of its 2024 incentive plan[13]. - The company will complete the transfer of 5.975 million shares to the 2024 employee stock ownership plan at a price of 8.07 yuan per share[13]. - The repurchase account holds 8,920,074 shares, accounting for 1.27% of the total share capital[12]. - The company has no preferred shareholders or significant changes in the top 10 shareholders due to margin trading[13]. - The company has not disclosed any related party relationships among the top 10 shareholders[12]. Operating Performance - The company's gross profit margin decreased due to a higher growth rate in operating costs (43.77%) compared to revenue growth (22.52%)[9]. - The sales revenue of the company's traditional Chinese medicine products increased significantly, with a 50.64% growth in Chinese medicine formula granules and a 26.39% increase in Chinese medicine pieces[9]. - Total operating revenue for the current period reached ¥824,425,237.08, an increase of 22.5% compared to ¥672,899,096.57 in the previous period[18]. - Total operating costs amounted to ¥623,213,469.79, up 20.1% from ¥519,085,030.36 in the prior period[18]. Other Comprehensive Income - The company’s other comprehensive income increased by 119.42% to ¥20,762.59 million, primarily due to the rise in market value of its investment in CARsgen Therapeutics Holdings Limited[8]. - The other comprehensive income attributable to the parent company is CNY 113,000,598.02, compared to a loss of CNY -8,161,468.92 in the previous period[19].

Financial Performance - The company's operating revenue for 2024 reached ¥2,577,878,166.87, representing a 32.71% increase compared to ¥1,942,440,446.03 in 2023[16]. - Net profit attributable to shareholders for 2024 was ¥507,771,934.85, up 32.60% from ¥382,936,093.79 in the previous year[16]. - The basic earnings per share for 2024 increased to ¥0.73, a rise of 32.73% from ¥0.55 in 2023[16]. - The total assets of the company at the end of 2024 were ¥3,991,955,854.40, reflecting a 10.06% growth from ¥3,627,038,970.51 at the end of 2023[16]. - The company's net assets attributable to shareholders increased by 1.47% to ¥2,768,884,681.97 at the end of 2024, compared to ¥2,728,743,064.49 in 2023[16]. - The cash flow from operating activities for 2024 was ¥297,047,240.40, showing a slight increase of 2.98% from ¥288,461,038.46 in 2023[16]. - The weighted average return on equity for 2024 was 18.55%, an increase of 4.74% from 13.81% in 2023[16]. - The company reported a net profit of ¥507,684,220.81 after deducting non-recurring gains and losses, which is a 35.89% increase from ¥373,610,235.02 in 2023[16]. Market and Industry Insights - The Chinese pharmaceutical industry saw a revenue of ¥29,762.7 billion in 2024, remaining flat year-on-year, with profits declining by 0.9% to ¥4,050.9 billion[25]. - The number of registered traditional Chinese medicine (TCM) applications reached 2,407 in 2024, with clinical submissions (IND) hitting 100, marking a 48.15% increase year-on-year[26]. - The market sales for the 2024 medical insurance drug list reached ¥1.2 trillion in 2023, with TCM contributing ¥255.5 billion, representing 20.53% of the total[26]. - The company is positioned to benefit from the increasing demand for TCM in chronic disease management and preventive healthcare, driven by an aging population and rising health awareness[27]. - The government continues to enhance support for the TCM industry, indicating a long-term growth opportunity in the sector[27]. Product Development and Innovation - The company’s main business includes the research, production, and sales of various traditional Chinese medicine products, including Wuling series and Bailing series[36]. - The company aims to enhance the quality of traditional Chinese medicine and promote high-quality development in the industry through innovation and reform[31]. - The company has developed a traceability system for over 100 traditional Chinese medicine varieties, with 438 national and provincial standard filings completed for traditional Chinese medicine formula granules[42]. - The company is conducting secondary development of Wuling Capsules for Alzheimer's treatment and is researching mild cognitive impairment in the elderly[38]. - The company has entered the registration process for two new drugs: Lingxiang Pian is in Phase II clinical trials, while the application for Jukapofen Calcium Granules is under review[45]. Corporate Governance and Management - The company has established a strict procurement management system, ensuring appropriate inventory levels based on production plans and sales conditions[43]. - The company has a diverse management team with backgrounds in pharmaceuticals, finance, and healthcare[142][143][144][145][146][147]. - The company is committed to improving information disclosure quality and enhancing investor relations management[127]. - The company has a dedicated audit committee to oversee internal and external audit communications and ensure compliance with internal control systems[132]. - The company has established an independent financial department and management system, ensuring no shared bank accounts with controlling shareholders[136]. Environmental and Social Responsibility - The company has been designated as a key pollutant discharge unit for water environment in 2024[178]. - The company has obtained an environmental permit from the Huzhou Ecological Environment Bureau, valid from November 29, 2024, to November 28, 2029[179]. - The company has implemented a wastewater treatment system that ensures compliance with discharge standards, with real-time monitoring of key indicators[182]. - The company continues to fulfill its social responsibility by actively participating in poverty alleviation and rural revitalization efforts, as detailed in the ESG report[185]. Future Outlook and Strategic Initiatives - The company aims to achieve a revenue target of RMB 10 billion by focusing on its core pharmaceutical business and expanding its product lines through innovation and acquisitions[99]. - The company plans to invest CNY 590 million in the "Intelligent Traditional Chinese Medicine Production Base Construction and Upgrade Project," which includes four sub-projects aimed at enhancing production capacity[93]. - The company will continue to implement a strategy of "one body and two wings," enhancing channel layout, market coverage, and talent acquisition to maximize market share and product coverage[107]. - The company is actively exploring digital transformation and enhancing its quality management systems to ensure product safety and effectiveness[52]. - The company recognizes the risk of industry policy changes and plans to adapt its business strategies accordingly to maintain competitiveness in the pharmaceutical sector[111].